Cardiovascular Treatment Equipment (Global Market)

Medical Equipment (Global Market)

Main Article: Medical Equipment (Global Market)

Cardiovascular Ultrasound Equipment (Global Market)

Main Article: Cardiovascular Ultrasound Equipment (Global Market)

2024: Global sales of cardiovascular treatment equipment hit $53.7 billion for the year

In 2024, the global market for cardiovascular equipment (CVD) reached $53.7 billion. Almost half of this amount fell on the North American region. Such data are presented in a study by Grand View Research, the results of which Zdrav.Expert reviewed in mid-September 2025.

One of the main drivers of the industry is the increasing prevalence of CVD. In May 2024, the World Health Organization (WHO) reported that such ailments are the main cause of disability and premature death in the European region, where CVD accounts for more than 42.5% of all deaths: this means that every day about 10 thousand people die from such diseases. Globally, millions of people die from CVD each year. So, according to estimates, 19.8 million people died from these diseases in 2022. Approximately 80% of global CVD deaths occur in low- and middle-income countries. Many residents of these regions are not covered by primary health care programs that identify and treat individuals with CVD risk factors. The observed trends lead to an increase in the demand for diagnostic equipment and specialized devices for the therapy of cardiovascular diseases.

Another significant stimulating factor is technological progress. Medical product companies are investing heavily in research and development to build next-generation devices such as bioresorbable stents, wearable heart monitors and advanced diagnostic equipment. Next-generation imaging systems improve the accuracy and efficiency of pathology detection, which contributes to improved treatment outcomes.

Artificial intelligence has a significant impact on the industry. By analyzing patient information from a variety of sources, including medical records and imaging data, neural networks enable the identification of potential early-stage health problems. At the same time, decision-making is accelerated and the number of errors associated with manual analysis of information is reduced. In addition, AI algorithms make it possible to form personalized therapy plans, taking into account the condition and individual characteristics of each patient. The integration of AI into wearable devices helps monitor the vital signs of the body, detecting deviations that may indicate the development of CVD.

The authors of the study segment the market into diagnostic and monitoring equipment, as well as surgical devices (coronary stents, catheters, implantable cardioverter defibrillators, valves, etc.). In 2024, the lion's share of revenue was provided by surgical products - 68.8%. Geographically, North America holds the lead with 47.7% of global costs. However, the highest growth rates are recorded in the Asia-Pacific region. Significant industry players on a global scale are:

• Abbott;
• GE HealthCare;
• Edwards Lifesciences;
• W. L. Gore & Associates;
• Siemens Healthcare;
• Biotronik SE & Co. KG;
• Canon Medical Systems;
• B. Braun SE;
• LivaNova;
• Cardinal Health;
• Medtronic;
• Boston Scientific.

In 2025, the market size is expected to reach $57.6 billion. Analysts at Grand View Research believe that in the future, the CAGR will be 7.8%. Thus, by 2033, costs may increase to $106.7 billion.^[1]

2020: Cardiovascular Disease Treatment and Diagnosis Equipment Market Size Reaches $53 Billion

The volume of the global market for equipment used in the treatment and diagnosis of cardiovascular diseases at the end of 2020 turned out to be $53 billion, slightly (by 0.3%) reduced compared to the previous year. Such data in August 2021 were released by Evaluate analysts specializing in health research.

The leader of the market in question was Medtronic, which in 2020 recorded a 20.4 percent share in the asset, which is 0.7 percentage points more than a year earlier. Second place went to Abbott Laboratories, which accounted for 14.6% of sales of equipment for the treatment and diagnosis of heart and vascular diseases. Compared to 2019, Abbott's share decreased by 2 percentage points.

The share of Boston Scientific fell by 1.1 percentage points, which in 2020 amounted to 11.1%. Next is Edwards Lifesciences, which controlled 8.2% of the market, which roughly corresponds to the result of a year ago. The top five was closed by Johnson & Johnson, whose share on an annualized basis increased by 0.1 percentage points, to 5.7%.

In total, the top 5 largest manufacturers of equipment for the treatment of cardiovascular diseases in 2020 occupied 60% of the market.

The market size for equipment for the treatment and diagnosis of cardiovascular diseases in 2020 reached $53 billion

This market in 2020 showed a decline due to the COVID-19 coronavirus pandemic, which led to the fact that a significant part of the resources of world health care was thrown into the fight against this infection. Under these conditions, heart and vascular operations, as well as diagnostic examinations, were delayed, and hospitals and clinics restrained the costs of the appropriate technique.

However, analysts are confident that this decline was temporary, and further sales of equipment for the treatment of cardiovascular diseases will grow, as more people around the world face stroke, cardiomyopathy, etc.

According to WHO data for 2020, coronary heart disease accounts for 16% of all deaths in the world. Since 2000, the largest increase in deaths has been attributed to coronary heart disease, increasing by more than 2 million to 8.9 million deaths. This high prevalence leads to enormous economic pressure on each country's health systems.

Cardiovascular Disease Treatment and Diagnosis Equipment Market Leaders

Moreover, the technologies used in the development of cardiac devices have improved significantly over the past decade, and the functionality of such devices has expanded. Thanks to this, more and more patients receive timely treatment and diagnoses. Artificial intelligence is one such advance with a significant positive impact on cardiology, thanks to improved diagnostic capabilities for some heart diseases.

The market in question is divided into cardiac diagnostic devices (electrocardiographs and remote cardiac monitoring machines) and surgical (used in operations). The latter segment is more consolidated and highly competitive. Large companies are leading here, but local manufacturers are trying to compete with giants. To counter small players, it is not uncommon for large manufacturers to buy them.

The largest market for such equipment remains the United States due to the high prevalence of cardiovascular diseases, the widespread use of minimally invasive procedures, government subsidies, an increase in the number of elderly people and high demand for devices for continuous monitoring of the health of "cores" at home.^[2]

Notes